Literature DB >> 954808

Turnover of acid dopamine metabolites in striatal and mesolimbic tissue of the rat brain.

B H Westerink, J Korf.   

Abstract

The subject of this study was the disappearance of 3, 4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) from the brain of rats treated with pargyline and pargyline in combination with tropolone. The DOPAC decline was exponential after pargyline treatment, while the HVA decline became a first order elimination when in addition to monoamine oxidase, catechol-O-methyl transferase was also inhibited. The turnover of the metabolites was calculated by multiplying the steady state level by the fractional rate constant (k). The DOPAC turnover was found to be 23.3 nmol/g/h in the corpus striatum and 22.6 nmol/g/h in the mesolimbic structures. The HVA turnover was 11.2 nmol/g/h in the corpus striatum and 6.7 nmol/g/h in the mesolimbic structures. The data showed that under control conditions DOPAC is only partially O-methylated to HVA, while the formation of HVA via the methoxytyramine pathway is unlikely. DOPAC turnover therefore probably approximates dopamine turnover.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954808     DOI: 10.1016/0014-2999(76)90032-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  In vivo labelling and axonal transport of monoamine oxidase in the rat basal ganglia using radioactive pargyline.

Authors:  J B Gramsbergen; J B Sebens; J Korf
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

2.  BRL 20596, a novel anilide with central dopamine antagonist activity.

Authors:  W Campbell; M S Clark; P J Mitchell; P L Needham; J M Semple
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Effects of striatal lesions with kainic acid on morphine-induced "catatonia" and increase of striatal dopamine turnover.

Authors:  U Havemann; M Winkler; E Genç; K Kuschinsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-08       Impact factor: 3.000

4.  3-Methoxytyramine: its suitability as an indicator of synaptic dopamine release.

Authors:  P C Waldmeier; J Lauber; W Blum; W J Richter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-01       Impact factor: 3.000

5.  Conditioning of pre- and post-synaptic behavioural responses to the dopamine receptor agonist apomorphine in rats.

Authors:  H G Möller; K Nowak; K Kuschinsky
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Pathways of dopamine metabolism in the rabbit caudate nucleus in vitro.

Authors:  A Zumstein; W Karduck; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-06       Impact factor: 3.000

7.  A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice.

Authors:  A Svensson; E Pileblad; M Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1991

8.  Tolerance to fluphenazine and supersensitivity to apomorphine in central dopaminergic systems after chronic fluphenazine decanoate treatment.

Authors:  S C Wheeler; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-06       Impact factor: 3.000

9.  Effect of lergotrile on 3,4-dihydroxyphenylacetic acid (DOPAC) concentration and dopamine turnover in rat brain.

Authors:  R W Fuller; K W Perry
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

10.  Probenecid sensitive pathway of elimination of dopamine and serotonin metabolites in CSF of the rat.

Authors:  J L Elghozi; E Mignot; K H Le Quan-Bui
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.